MedTrace Logo

A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

NCT00073476 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2006-06-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.

Conditions

Interventions

DRUG

traxiprodil (CP-101,606)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2005-02-28

Countries

  • United States
  • Estonia
  • Germany
  • Hungary
  • Italy
  • Portugal
  • Singapore
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00073476 on ClinicalTrials.gov